Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
Key facts
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Where
- Switzerland3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 272 people enrolled
- Started
- 19 Jul 2018
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Record updated
- 13 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with scheduled elective bariatric surgery or redo surgery after bariatric interventions
- Written informed consent
Who cannot take part
- Myocardial infarction, transient ischemic attack or stroke within 6 months of study entry
- Uncontrolled hypertension
- DVT and/or PE in the patient history
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.
Read full original descriptionShow less
The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.
All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.
In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.
The 2 groups in the trial
- A: Rivaroxaban short armExisting treatment, for comparison
7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
Treatment: Rivaroxaban 10 MG Oral Tablet [Xarelto]
- B: Rivaroxaban long armExisting treatment, for comparison
28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o. Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28
Treatment: Rivaroxaban 10 MG Oral Tablet [Xarelto]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
- Publications
- Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial.JAMA network open, 2023
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.The Cochrane database of systematic reviews, 2022
- Record updated
- 13 November 2024